Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bluebird Lenti-D Data Give Gene Therapy Business Another Boost

Results Show Continued Positive Safety, Efficacy Profile

Executive Summary

The news comes less than a week after data partially exonerated its other gene therapy in a cancer scare announced in February.

You may also be interested in...



EU Crunch Time For Bluebird’s Neurodegenerative Disorder Gene Therapy

The EU could become the first market in which eli-cel is approved if the gene therapy for cerebral adrenoleukodystrophy this week passes muster with the European Medicines Agency.

PTC Therapeutics' Gene Therapy Plans Hit By Pandemic

PTC Therapeutics is one of many companies in the life sciences sector whose regulatory targets have been adversely affected by the coronavirus pandemic.

Three Cell And Gene Therapies Reach Critical Review Stage In EU

A number of advanced therapies are likely to be approved in the EU this year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel